摘要
目的探讨类风湿因子(RF)、抗环瓜氨酸肽抗体(A-CCP)、血小板计数(PLT)联合检测在诊断类风湿关节炎(RA)中的意义。方法简单随机选取2018年6月—2019年6月在该院就诊的RA患者46例(RA组),同时选取同期其他非RA性风湿病患者46例(非RA组)为研究对象,通过检测RF、抗CCP抗体、血小板计数水平及阳性率,比较3种指标在类风湿关节炎诊断中的意义。结果RA组患者的RF、抗CCP抗体、血小板计数水平分别为(86.4±45.7)IU/mL、(86.2±67.6)RU/mL、(368.1±102.8)×10^(9)/L,显著高于非RA组(15.6±8.5)IU/mL、(4.1±2.2)RU/mL、(239.3±98.3)×10^(9)/L,差异有统计学意义(t=9.700、8.200、6.100,P<0.001);RA组患者RF、抗CCP抗体、血小板计数阳性率分别为89.1%、82.6%、78.3%,显著高于非RA组13.0%、6.5%、32.6%,差异有统计学意义(χ^(2)=53.300、53.900、19.400,P<0.01)。结论RF、抗CCP抗体、血小板计数三者联合检测可提高类风湿关节炎的诊断率,对类风湿关节炎的诊断具有重要意义。
Objective To explore the significance of combined detection of rheumatoid factor(RF),anti-cyclic citrullinated peptide antibody(A-CCP)and platelet count(PLT)in the diagnosis of rheumatoid arthritis(RA).Methods simple ramolomly selected 46 RA patients(RA group)who were in the hospital from June 2018 to June 2019,and selected 46 other non-RA rheumatism patients(non-RA group)as the research objects.CCP antibody,platelet count level and positive rate,compared the significance of three indicators in the diagnosis of rheumatoid arthritis.Results The levels of RF,anti-CCP antibodies and platelet counts in the RA group were(86.4±45.7)IU/mL,(86.2±67.6)RU/mL,and(368.1±102.8)×10^(9)/L,which were significantly higher than those in the non-RA group(15.6±8.5)IU/mL,(4.1±2.2)RU/mL,(239.3±98.3)×10^(9)/L,the difference was statistically significant(t=9.700,8.200,6.100,P<0.001);The Positive rates of RF,anti-ccp antibodies,and platelet counts in the RA group were 89.1%,82.6%,and 78.3%respectively,which were significantly higher than the non-RA group of 13.0%,6.5%,and 32.6%.The difference were statistically significant(χ^(2)=53.300,53.900,19.400,P<0.01).Conclusion The combined detection of RF,anti-CCP antibody,and platelet count can improve the diagnosis rate of rheumatoid arthritis and is of great significance for the diagnosis of rheumatoid arthritis.
作者
杨二丽
YANG Er-li(Department of Rheumatology and Immunology,Affiliated Hospital of Chifeng University,Chifeng,Inner Mongolia Autonomous Region,024005 China)
出处
《中外医疗》
2021年第2期175-177,共3页
China & Foreign Medical Treatment
